Bleeding Disorders

A collection of features and news articles published in ASH Clinical News related to bleeding disorders.

Investigation Finds Hemophilia Gene Therapy Likely Did Not Cause Hepatocellular Carcinoma

An investigation found that etranacogene dezaparvovec was unlikely to have caused a case of hepatocellular carcinoma (HCC) in a participant of the HOPE-B trial,...
WIB_icon

International Working Group Publishes Revised Definitions for Remission, Relapse in Immune TTP

The International Working Group (IWG) for thrombotic thrombocytopenic purpura (TTP) has published revised definitions for response, exacerbation, remission, and relapse of immune-mediated TTP (iTTP)...
On location

TPO-RAs and ITP: Eltrombopag Induces High Efficacy, But Avatrombopag Offers Advantages

A pair of studies presented at the 2020 American Society of Hematology Annual Meeting analyzed the thrombopoietin receptor agonist (TPO-RA) eltrombopag in two settings:...

DDAVP Prevents Post-Intervention Bleeding Complications in Patients With Low von Willebrand Factor Levels

A recent study suggests 1-desamino-8-D-arginine vasopressin (DDAVP) prevents bleeding in patients with low von Willebrand factor (VWF) levels undergoing major and minor elective procedures....

VLX-1005 Receives Orphan Drug Designation

The FDA granted orphan drug designation to VLX-1005 as thrombosis prophylaxis in patients with heparin-induced thrombocytopenia (HIT). According to its manufacturer, Veralox Therapeutics, preclinical data...

Are Rare Cases of Immune Thrombocytopenia Linked to the COVID Vaccine?

A small number of patients have developed immune thrombocytopenia (ITP) after receiving the Pfizer/BioNTech and Moderna coronavirus vaccines. Whether the onset of the condition...
On location

New HOPE for Hemophilia B: One-Time Gene Therapy Abolishes Bleeding in Most Patients

A single dose of the gene therapy drug etranacogene dezaparvovec increased factor IX (FIX) activity levels, and eliminated the need for prophylactic FIX, in...
On location

Adding Mycophenolate to Corticosteroids Improves Response as Frontline ​Option in Immune Thrombocytopenia

In results from the randomized, controlled FLIGHT trial, patients with immune thrombocytopenia (ITP) who received mycophenolate mofetil (MMF) plus corticosteroids as first-line therapy were...

Does Blood Group Affect Risk of Bleeding Events or Bleeding Severity?

According to research published in Blood Advances, people who experience bleeding of unknown causes are 48% more likely to have blood group O, compared...

Steven Pipe: Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Steven Pipe, MD, shares safety and efficacy data from a phase III study of etranacogene dezaparvovec gene therapy in patients with hemophilia B.